Genmab says Phase 3 EPCORE DLBCL-2 trial shows epcoritamab plus R-CHOP cuts progression or death risk 51% in newly diagnosed DLBCL

• Genmab, AbbVie reported positive topline Phase 3 results for epcoritamab with R-CHOP in newly diagnosed DLBCL patients.
• Trial met its main goal, showing a meaningful delay in disease worsening versus R-CHOP alone in higher-risk patients.
• Safety profile looked broadly consistent with known effects of the regimen, supporting potential use in frontline treatment.
• Results have not yet been presented; data will be submitted for presentation at a future medical meeting.
• Companies plan to engage regulators globally, setting up potential filings for an investigational frontline combination.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genmab A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610051449PRIMZONEFULLFEED1001276411) on October 05, 2026, and is solely responsible for the information contained therein.